ResultsIQ

ResultsIQ › Latest results › Insecticides (India) Limited

Insecticides (India) Limited Q2 FY27 earnings call summary

NSE: INSECTICID · BSE: 532851

Earnings call of 5 Nov 2026, summarised by AI from the filing.

Kaeros brand turnover targeted above ₹125 cr this fiscal, stand-alone around ₹200 cr.

Key takeaways

  1. Kaeros guidance Kaeros brand turnover targeted above ₹125 cr this fiscal, stand-alone around ₹200 cr.
  2. Premiumisation Premium products above 60% of portfolio support margins, with a 70% target.
  3. Working capital Working capital days rose to 158 from 151, with inventory and debtors elevated.

Original filing on BSE

Insecticides (India) Limited Q2 FY27 results

As filed: Revenue ₹686 cr (+8% year on year), EBITDA ₹92.4 cr (+4% year on year), PAT ₹56.2 cr (−5% year on year), EBITDA margin 13.5% (−48 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹612 cr (−12% year on year), EBITDA ₹67.6 cr (−20% year on year), PAT ₹43.9 cr (−24% year on year), EBITDA margin 11.1% (−110 bps). Score 25 of 100, Below trend. Revenue and profit growth were well below the company's own trend; EBITDA growth was below it. EBITDA margin fell 110 bps year on year. Share price after the results: −5.7% in 30 days (Nifty 500: −3.3%).
  • Q4 FY26: Revenue ₹426 cr (+19% year on year), EBITDA ₹25.6 cr (−9% year on year), PAT ₹11.7 cr (−16% year on year), EBITDA margin 6.0% (−179 bps). Score 47 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 179 bps year on year. Other income 29% of PBT. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −13.9% in 28 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹385 cr (+8% year on year), EBITDA ₹27.4 cr (−12% year on year), PAT ₹10.5 cr (−38% year on year), EBITDA margin 7.1% (−154 bps). Score 33 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 154 bps year on year. Revenue fell 40% from last quarter. Share price after the results: −6.1% in 28 days (Nifty 500: +0.1%).
  • Q2 FY26: Revenue ₹638 cr (+2% year on year), EBITDA ₹89.0 cr (0% year on year), PAT ₹59.0 cr (−3% year on year), EBITDA margin 14.0% (−24 bps). Score 32 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 24 bps year on year. Revenue fell 8% from last quarter. Share price after the results: +2.8% in 30 days (Nifty 500: +0.2%).
  • Q1 FY26: Revenue ₹691 cr (+5% year on year), EBITDA ₹84.0 cr (+18% year on year), PAT ₹58.0 cr (+18% year on year), EBITDA margin 12.2% (+135 bps). Score 40 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin rose 135 bps year on year. Profit rose ₹9.0 cr on a year ago, against ₹20.0 cr the year before. Share price after the results: −24.5% in 30 days (Nifty 500: +2.8%).
  • Q4 FY25: Revenue ₹359 cr (+32% year on year), EBITDA ₹28.0 cr (+211% year on year), PAT ₹14.0 cr (+75% year on year), EBITDA margin 7.8% (+450 bps). Score 85 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 450 bps year on year. Tax rate 36%. Profit fell 18% from last quarter. Share price after the results: +15.7% in 30 days (Nifty 500: +3.7%).
  • Q3 FY25: Revenue ₹358 cr (0% year on year), EBITDA ₹31.0 cr (+19% year on year), PAT ₹17.0 cr (+42% year on year), EBITDA margin 8.7% (+140 bps). Score 45 of 100, In line with trend. Revenue growth was in line with the company's own trend. EBITDA margin rose 140 bps year on year. Revenue fell 43% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Insecticides (India) Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.